Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
These are comfortable measurements that avoid both the very small units of 5mg/mL and the near-capacity units of 2.5mg/mL
Recent GLP-1 Weight Loss Drug Market Developments: Novo Nordisk, Eli Lilly, Amgen, and FDA Lead 20252026 April 2026: Eli Lilly submitted the orforglipron New Drug Application to the FDA for obesity treatment, reporting 14.7% body weight reduction in the ATTAIN-WEIGHT1 Phase 3 trial at the 45mg dose the first oral small molecule GLP-1 receptor agonist NDA submission for dedicated obesity pharmacological treatment in the United States
Some people regain weight even after surgery
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the companys Annual Report on Form 10-K for the year ended December 31, 2023 and the companys other filings with the Securities and Exchange Commission (SEC) available at the SECs Internet site (www.sec.gov)
Trulicity (dulaglutide) EPAR Product Information
During illness ('sick days'), patients should maintain hydration and follow standard diabetes sick-day rules
